论文部分内容阅读
目的:通过比较运用不同标准评价乳腺癌患者维生素D状态的差异及防治现状,找寻最佳证据以指导临床规范补充维生素D.方法:对87例女性乳腺癌患者进行回顾性研究,记录患者年龄、体重指数、25-羟基维生素D3测定值、合并危险因素和药物防治情况的信息,25-羟基维生素D3测定值分别依照来自中国和国际的两个判定标准进行评价,所有数据用Excell表格进行处理,用例数及百分率描述数据.结果:87例女性乳腺癌患者中,参照中国指南16例(18.39％)维生素D缺乏;25例(28.74％)维生素D不足;46例(52.87％)维生素D水平适宜.参照国际指南41例(47.12％)维生素D缺乏;34例(39.08％)维生素D不足;12例(13.80％)维生素D水平适宜.87例患者中有37例口服碳酸钙D3片做为维生素D补充主要来源.结论:两种评价标准均显示乳腺癌患者维生素D缺乏或不足存在一定发生率,临床医生应结合患者个体情况,对需要进行维生素D补充的乳腺癌患者选择合适的药物和剂量.“,”Objective:By comparing the differences in vitamin D status evaluated under different criteria,provide references to the prevention and treatment of vitamin D supplement in breast cancer patients.Methods:A retrospective study was conducted in 87 cases of female breast cancer patients.The data of age,body mass index,the levels of 25-hydroxyvitamin D3,combined risk factors and drug intervention were recorded.The levels of 25-hydroxyvitamin D3 were evaluated according to China and international criteria respectively.All data was processed with excel.Results:According to Chinese guideline,16 cases (18.39％) were vitamin D deficiency;25 cases (28.74％)were insufficient vitamin D and 46 cases (52.87％) with suitable vitamin D level.Forty-one patients (47.12％) with vitamin D deficiency,34 (39.08％) with insufficient vitamin D,and 12 (13.80％) with suitable vitamin D levels were found among the 87 patients,according to international guideline.37 cases among 87 patients had oral calcium carbonate D3 as the main source of vitamin D supplementation.Conclusion:Both evaluation criteria showed that there were certain incidence of vitamin D deficiency and insufficiency in breast cancer patients.Clinicians should choose appropriate drugs and doses for breast cancer patients who need vitamin D supplementation.